Colon cancer, the second leading cause of cancer deaths in the United States, begins in the large intestine
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
Invoicing, for example, was a nightmare
McLeod, T.E
Additional coverage pathways Because UHC evaluates each medication under its own clinical policy bulletin, additional FDA-approved indications can open separate coverage pathways sometimes through medical benefit rather than pharmacy benefit
